Curated News
By: NewsRamp Editorial Staff
December 17, 2025
Soligenix Reports Positive Psoriasis Trial Results for SGX302 Gel Formulation
TLDR
- Soligenix's SGX302 gel shows superior efficacy over its ointment formulation in psoriasis trials, offering investors a potential advantage in the rare disease treatment market.
- Soligenix's Phase 2a trial demonstrated SGX302's optimized topical gel formulation improved clinical scores and quality-of-life measures with no drug-related adverse events.
- SGX302's non-carcinogenic, non-mutagenic properties could provide a safer therapeutic option for psoriasis patients, improving treatment outcomes and quality of life.
- Soligenix's synthetic hypericin gel for psoriasis shows promising results, potentially offering a novel, non-toxic treatment derived from a natural compound.
Impact - Why it Matters
This development matters because psoriasis affects millions worldwide, often causing significant physical discomfort and psychological distress. Current treatments can have serious side effects or limited efficacy. SGX302's non-carcinogenic, non-mutagenic profile represents a potentially safer alternative, addressing a critical unmet need in dermatology. For patients, this could mean more effective management of symptoms with fewer health risks. For the healthcare system, it offers a new therapeutic option that might reduce long-term complications. The trial's success also validates Soligenix's approach to rare disease treatment, potentially accelerating development of similar therapies. As psoriasis has no cure, advancements like this significantly improve quality of life and treatment outcomes.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has reported promising extended results from its ongoing Phase 2a trial for SGX302 (synthetic hypericin) in treating mild-to-moderate psoriasis. The trial evaluated an optimized topical gel formulation, which demonstrated strong safety and efficacy profiles. The gel was well tolerated with no drug-related adverse events and showed improvements across multiple clinical measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores. These results were comparable to or exceeded those observed with the prior ointment formulation, supporting continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis patients. The company's focus on rare diseases with unmet medical needs positions this development as significant for the dermatology treatment landscape.
Soligenix operates through two main business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment is advancing HyBryte™ (SGX301) for cutaneous T-cell lymphoma and expanding synthetic hypericin into psoriasis treatment. It also includes development programs for dusquetide (SGX942) for inflammatory diseases and SGX945 for Behçet's Disease. The Public Health Solutions segment focuses on vaccine candidates like RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19 prevention, utilizing the proprietary ThermoVax® heat stabilization platform. This segment has been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
The news was distributed through NetworkNewsWire (NNW), a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. NNW provides comprehensive financial news and content distribution services, including wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release features, social media distribution through IBN's extensive network, and tailored corporate communications solutions. This platform helps companies like Soligenix reach investors, journalists, and the general public effectively. For more detailed information, readers can access the full press release through the provided hyperlink or visit the company's newsroom for the latest updates relating to SNGX.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Reports Positive Psoriasis Trial Results for SGX302 Gel Formulation
